Drug Profile
Research programme: protein-tyrosine kinase receptor antagonists - Biovitrum
Alternative Names: BVT I; BVT IILatest Information Update: 18 Mar 2009
Price :
$50
*
At a glance
- Originator Biovitrum
- Class
- Mechanism of Action Receptor protein-tyrosine kinase antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Acute myeloid leukaemia
Most Recent Events
- 15 Jun 2008 Preclinical trials in Acute myeloid leukaemia in Sweden (unspecified route)